TC
ABBV icon

Trilogy Capital’s AbbVie ABBV Stock Holding History

Trilogy Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87M Buy
23,338
+1,912
+9% +$411K 0.23% 74
2026
Q1 		$4.66M Buy
21,426
+430
+2% +$95.4K 0.21% 79
2025
Q4 		$4.8M Sell
20,996
-241
-1% -$54.9K 0.21% 72
2025
Q3 		$4.92M Sell
21,237
-363
-2% -$73.9K 0.23% 65
2025
Q2 		$4.01M Sell
21,600
-494
-2% -$91.8K 0.2% 75
2025
Q1 		$4.63M Buy
22,094
+6,270
+40% +$1.22M 0.24% 61
2024
Q4 		$2.81M Buy
15,824
+11,281
+248% +$2.07M 0.14% 112
2024
Q3 		$897K Sell
4,543
-151
-3% -$28.2K 0.05% 179
2024
Q2 		$805K Sell
4,694
-73
-2% -$12.1K 0.04% 180
2024
Q1 		$868K Sell
4,767
-14,901
-76% -$2.57M 0.05% 159
2023
Q4 		$3.05M Sell
19,668
-194
-1% -$28.3K 0.19% 85
2023
Q3 		$2.96M Buy
19,862
+117
+0.6% +$17.2K 0.2% 69
2023
Q2 		$2.84M Buy
19,745
+761
+4% +$112K 0.18% 81
2023
Q1 		$3.03M Buy
18,984
+3,058
+19% +$468K 0.22% 65
2022
Q4 		$2.57M Buy
15,926
+2,289
+17% +$351K 0.18% 70
2022
Q3 		$1.83M Buy
13,637
+1,618
+13% +$232K 0.16% 64
2022
Q2 		$1.84M Sell
12,019
-460
-4% -$70.3K 0.16% 56
2022
Q1 		$2.02M Buy
12,479
+1,890
+18% +$275K 0.15% 67
2021
Q4 		$1.43M Buy
10,589
+453
+4% +$53.5K 0.11% 70
2021
Q3 		$1.09M Buy
10,136
+29
+0.3% +$3.31K 0.08% 78
2021
Q2 		$1.19M Buy
10,107
+2,290
+29% +$258K 0.09% 74
2021
Q1 		$846K Buy
7,817
+1,260
+19% +$135K 0.06% 105
2020
Q4 		$703K Buy
6,557
+83
+1% +$7.98K 0.06% 96
2020
Q3 		$567K Sell
6,474
-360
-5% -$33.9K 0.05% 93
2020
Q2 		$680K Sell
6,834
-171
-2% -$15.1K 0.07% 73
2020
Q1 		$593K Sell
7,005
-1,766
-20% -$150K 0.07% 76
2019
Q4 		$780K Buy
8,771
+572
+7% +$47.5K 0.08% 81
2019
Q3 		$612K Buy
8,199
+968
+13% +$66.4K 0.07% 89
2019
Q2 		$518K Buy
7,231
+698
+11% +$54.9K 0.06% 91
2019
Q1 		$526K Buy
+6,533
New +$534K 0.06% 92
2018
Q4 		– Sell
-224
Closed -$21K – 134
2018
Q3 		$21K Buy
224
+1
+0.4% +$95 ﹤0.01% 267
2018
Q2 		$21K Sell
223
-4
-2% -$391 ﹤0.01% 243
2018
Q1 		$21K Sell
227
-7,933
-97% -$871K ﹤0.01% 220
2017
Q4 		$789K Buy
+8,160
New +$769K 0.13% 47

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Trilogy Capital's ABBV Position: Q2 2026 in Review

Trilogy Capital increased its AbbVie (ABBV) stake by 8.9% in Q2 2026, buying an estimated $411K and bringing the position to 23,338 shares worth $5.87M. The position accounts for 0.23% of the portfolio, ranked #74.

Trilogy Capital first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. 803 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Trilogy Capital held 23,338 shares of AbbVie worth $5.87M as of Q2 2026.
  • Trilogy Capital bought 1,912 AbbVie shares in Q2 2026, an estimated $411K.
  • AbbVie made up 0.23% of Trilogy Capital's portfolio in Q2 2026, its #74 holding.
  • Trilogy Capital first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
  • 803 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Trilogy Capital's 13F filing for Q2 2026, filed 6 Jul 2026.